Literature DB >> 10028315

Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis.

H J Metzner1, P Hermentin, T Cuesta-Linker, S Langner, H G Müller, J Friedebold.   

Abstract

In order to provide patients with von Willebrand disease a factor VIII (FVIII)/von Willebrand factor (vWF) concentrate of reproducible quality, an SDS-agarose gel electrophoresis method has been established to determine the content of the high molecular weight multimers (band 11 and higher) of vWF. This method has been used to characterize the content of high molecular weight vWF multimers in Humate P/Haemate P, a commercial FVIII/vWF concentrate. The average content of high molecular weight vWF multimers of 47 batches of Humate P/Haemate P has been determined to be 84.1% of the corresponding bands in normal human plasma. Use of this multimer analysis method for the characterization of five further commercial products revealed clear differences with respect to the high molecular weight vWF multimer content. Furthermore, there is a linear correlation (r2 = 0.73) between the content of high molecular weight vWF multimers and the specific activity of vWF (determined as vWF:RCoF/vWF:Ag). The method described here for analysis of the content of high molecular weight vWF multimers is a reliable and reproducible method to characterize this class of factor concentrates with respect to vWF multimer composition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10028315     DOI: 10.1046/j.1365-2516.1998.0040s3025.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Evaluation of the effect of 6 von Willebrand factor concentrates on platelet adhesion to human vein segments under flow conditions.

Authors:  Wolfgang Mouton; Jerzy Madon; Joerg Fehr; Thomas Bombeli
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

2.  Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized.

Authors: 
Journal:  P T       Date:  2010-01

3.  Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice.

Authors:  Q Shi; E L Kuether; J A Schroeder; S A Fahs; R R Montgomery
Journal:  Haemophilia       Date:  2012-01-04       Impact factor: 4.287

4.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Authors:  Pier Mannuccio Mannucci; Christine Kempton; Carolyn Millar; Edward Romond; Amy Shapiro; Ingvild Birschmann; Margaret V Ragni; Joan Cox Gill; Thynn Thynn Yee; Robert Klamroth; Wing-Yen Wong; Miranda Chapman; Werner Engl; Peter L Turecek; Tobias M Suiter; Bruce M Ewenstein
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 5.  Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.

Authors:  Natalie J Carter; Lesley J Scott
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.